Medicare Enrolled
Dr. Mark Abate, M.D.
Hematology & Oncology · Santa Barbara, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Abate from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abate?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Abate
Dr. Mark Abate is a hematology & oncology specialist in Santa Barbara, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Abate performed 3,584 Medicare services across 565 unique beneficiaries.
Between the years covered by Open Payments, Dr. Abate received a total of $16,825 from 57 pharmaceutical and/or device companies across 350 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Abate is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 35% volume in CA
$16,825 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,584
Medicare services
Top 35% in CA for hematology & oncology
565
Unique beneficiaries
$35
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~189 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,316 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
558 | $103 | $353 |
| Anti-nausea injection (Aloxi/palonosetron) | 500 | $1 | $9 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
312 | $65 | $189 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
195 | $117 | $486 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
150 | $14 | $65 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
127 | $12 | $69 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
85 | $53 | $199 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
77 | $26 | $106 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
66 | $23 | $80 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
65 | $69 | $249 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
45 | $96 | $339 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
40 | $22 | $85 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
17 | $29 | $155 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
16 | $137 | $453 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
15 | $107 | $357 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.0% high complexity
58.4% medium
31.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,825
Total received (2018-2024)
Avg $2,404/year across 7 years
Top 24% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
350
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,751 (93.6%)
Other
Charitable contributions, space rental, and other categories
$684 (4.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$390 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,152
2023
$2,693
2022
$2,010
2021
$396
2020
$484
2019
$3,094
2018
$3,995
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$668
Janssen Biotech, Inc.
$363
AstraZeneca Pharmaceuticals LP
$336
E.R. Squibb & Sons, L.L.C.
$321
Sekisui Diagnostics, LLC
$300
SOBI, INC
$261
Gilead Sciences, Inc.
$231
Astellas Pharma US Inc
$220
Lilly USA, LLC
$215
Alexion Pharmaceuticals, Inc.
$184
ABBVIE INC.
$176
Apellis Pharmaceuticals, Inc.
$175
PFIZER INC.
$143
Alnylam Pharmaceuticals Inc.
$134
Agios Pharmaceuticals, Inc.
$92
EMD Serono, Inc.
$88
Takeda Pharmaceuticals U.S.A., Inc.
$51
GlaxoSmithKline, LLC.
$42
Genentech USA, Inc.
$30
Daiichi Sankyo Inc.
$29
Incyte Corporation
$29
Celgene Corporation
$26
Genmab U.S., Inc.
$20
Melinta Therapeutics, LLC
$18
Top 3 companies account for 32.9% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,521
E.R. Squibb & Sons, L.L.C.
$1,253
AstraZeneca Pharmaceuticals LP
$1,087
Sekisui Diagnostics, LLC
$1,005
Novartis Pharmaceuticals Corporation
$989
Alexion Pharmaceuticals, Inc.
$952
Astellas Pharma US Inc
$754
PFIZER INC.
$691
Lilly USA, LLC
$676
Incyte Corporation
$434
TESARO, Inc.
$404
Amgen Inc.
$372
Gilead Sciences, Inc.
$367
Seagen Inc.
$323
Genentech USA, Inc.
$322
GENZYME CORPORATION
$297
AbbVie, Inc.
$287
EMD Serono, Inc.
$286
AbbVie Inc.
$278
Takeda Pharmaceuticals U.S.A., Inc.
$274
SOBI, INC
$261
Celgene Corporation
$260
Pharmacyclics LLC, An AbbVie Company
$248
Clovis Oncology, Inc.
$213
GlaxoSmithKline, LLC.
$213
Merck Sharp & Dohme Corporation
$211
EISAI INC.
$202
Janssen Scientific Affairs, LLC
$182
Regeneron Healthcare Solutions, Inc.
$179
ABBVIE INC.
$176
Apellis Pharmaceuticals, Inc.
$175
ADC Therapeutics America, Inc.
$166
PORTOLA PHARMACEUTICALS, INC.
$147
Alnylam Pharmaceuticals Inc.
$134
Bayer HealthCare Pharmaceuticals Inc.
$128
Exelixis Inc.
$115
Medtronic USA, Inc.
$114
Eisai Inc.
$105
Jazz Pharmaceuticals Inc.
$104
Janssen Pharmaceuticals, Inc
$102
ImmunoGen, Inc.
$101
Spectrum Pharmaceuticals Inc.
$96
Agios Pharmaceuticals, Inc.
$92
Puma Biotechnology, Inc.
$87
Progenics Pharmaceuticals, Inc.
$70
Stemline Therapeutics Inc.
$66
McKesson Specialty Care Distribution, LLC
$59
Daiichi Sankyo Inc.
$52
BeiGene USA, Inc.
$38
Rigel Pharmaceuticals, Inc.
$25
EUSA Pharma (US) LLC
$24
Genmab U.S., Inc.
$20
JAZZ PHARMACEUTICALS INC.
$20
Flowonix Medical Incorporated
$19
Melinta Therapeutics, LLC
$18
Welch Allyn
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
Top 3 companies account for 23.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ANDEXXA · Abraxane · Avastin · BAVENCIO · BENLYSTA · BEVYXXA · BOSULIF · BRUKINSA · CABOMETYX · CALQUENCE · CARVYKTI · CYRAMZA · DARZALEX · DOPTELET · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · ENHERTU · EPKINLY · ERLEADA · Elahere · Empaveli · Enhertu · Epkinly · Erleada · FASLODEX · FRUZAQLA · GAZYVA · GILOTRIF · GIVLAARI · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · Imbruvica · Inrebic · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · Lupron · MEKINIST · NINLARO · Nerlynx · Neulasta · None · ONUREG · OPDIVO · OSTEOCOOL RF ABLATION · PROMACTA · PYLARIFY · PYRUKYND · Padcev · Pomalyst · Prolia · Prometra II · REBLOZYL · Rezzayo · Rubraca · SARCLISA · SCEMBLIX · SOLIRIS · Sylvant · TAGRISSO · TECVAYLI · TEPMETKO · Tavalisse · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vyloy · XARELTO · XOSPATA · XTANDI · Xofigo · Xospata · Xtandi · ZEJULA · ZEPZELCA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
18
Per 100K population
4.1
County median income
$95,977
Nearest hospital
SANTA BARBARA COTTAGE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Abate is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Abate experienced with dexamethasone injection (steroid)?
Based on Medicare claims data, Dr. Abate performed 1,316 dexamethasone injection (steroid) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Abate receive payments from pharmaceutical companies?
Yes. Dr. Abate received a total of $16,825 from 57 companies across 350 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abate's costs compare to other hematology & oncology specialists in Santa Barbara?
Dr. Abate's average Medicare payment per service is $35. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abate) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Santa Barbara
Browse hematology & oncology specialists in Santa Barbara ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology